Ocular Therapeutix, Inc. Common Stock (OCUL) Stock
NASDAQ · OCUL
7.51
Fundamentals
Market cap
$2.12B
Price / Earnings ratio
-7.2x
Price / Sales ratio
41.4x
Price / Book ratio
4.2x
Return on assets
-48.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
NeutralOCULSeptember 23, 2026
MarketBeatNeutral
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
OCUL

Stocktwits
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
NeutralOCULAugust 17, 2026
StocktwitsNeutral
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
OCUL

Zacks Investment Research
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
NeutralOCULAugust 3, 2026
Zacks Investment ResearchNeutral
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
OCUL

MarketBeat
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
NeutralOCULJuly 23, 2026
MarketBeatNeutral
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
OCUL
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
62M41M21M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
970M640M320M0
Revenue to Profit
2025$52.0M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-265.9M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
NeutralOCULSeptember 23, 2026
MarketBeatNeutral
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
OCUL

Stocktwits
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
NeutralOCULAugust 17, 2026
StocktwitsNeutral
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
OCUL

Zacks Investment Research
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
NeutralOCULAugust 3, 2026
Zacks Investment ResearchNeutral
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
OCUL

MarketBeat
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
NeutralOCULJuly 23, 2026
MarketBeatNeutral
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
OCUL

Stocktwits
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
NeutralOCULJune 17, 2026
StocktwitsNeutral
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
OCUL

The Motley Fool
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
NeutralOCULJune 15, 2026
The Motley FoolNeutral
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
OCUL

Zacks Investment Research
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
NeutralOCULMay 5, 2026
Zacks Investment ResearchNeutral
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
OCUL

Reuters
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
NeutralOCULMarch 20, 2026
ReutersNeutral
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
OCUL

The Motley Fool
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
NeutralOCULMarch 18, 2026
The Motley FoolNeutral
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
OCUL

Reuters
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
NeutralOCULFebruary 17, 2026
ReutersNeutral
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
OCUL
About Ocular Therapeutix, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees325
CEODr. Pravin U. Dugel M.D.
IPO DateJul 25, 2014
HeadquartersBedford, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO | 1964 |
| Mr. Donald Notman Jr. | Chief Operating Officer (Leave of Absence) | — |
| Mr. Steve Meyers | Chief Commercial Officer | — |
| Mr. Sanjay Nayak MBBS, Ph.D. | Chief Strategy Officer | 1970 |
| Dr. Nadia K. Waheed M.D., M.P.H. | Chief Medical Officer | 1977 |
| Mr. Jason Robins | CFO & Principal Accounting Officer | 1977 |
| Dr. Peter K. Jarrett Ph.D. | Chief Technical Officer | 1957 |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer | 1961 |
| Mr. William S. Slattery Jr. | Vice President of Investor Relations | — |
| Mr. Todd D.C. Anderman J.D. | Chief Legal Officer & Corporate Secretary | 1982 |
Fundamentals
Valuation
Market cap$2.12B
Price-to-sales ratio41.43
Price-to-book value4.15
Price-earnings ratio-7.20
Return on Equity-65.00%
Return on Sales-536.00%
Return on Assets-48.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-1.40
Income Statement
Average volume2,156,346
EBITDA$-274.25M
1 year high (52w)$16.44
1 year low (52w)$6.23
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$24.00
Est return
148.70%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.4 | -36.0 | -3.4 | +10.3 | ||||||||
| 2022 | -23.0 | -2.6 | -10.0 | -26.4 | -21.4 | +32.2 | +9.5 | +18.4 | -21.4 | -11.7 | -19.9 | -7.9 |
| 2023 | +40.1 | +56.1 | -13.2 | +18.3 | +3.6 | -19.6 | -9.2 | -13.9 | -18.9 | -3.4 | -22.3 | +66.4 |
| 2024 | +1.0 | +91.6 | -15.3 | -45.5 | +13.5 | +24.1 | +27.0 | +9.3 | +4.2 | +16.2 | -4.8 | -12.6 |
| 2025 | -11.9 | -5.4 | +23.6 | +26.9 | -6.1 | +14.4 | +27.3 | +2.4 | -8.0 | +5.6 | +6.5 | +3.7 |
| 2026 | -22.7 | -2.3 | -22.9 | +12.5 | -4.5 | +10.0 | -13.7 | +24.9 | -8.7 |



